Results 281 to 290 of about 681,627 (391)

Human immunodeficiency virus (HIV) infection epidemic: medical and social issues and the unresolved dilemmas.

, 1993
V Idemyor
openalex  

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Unpacking vulnerability to sexually transmitted infections (STIs)/human immunodeficiency virus (HIV) among adolescent girls and young women in India: A qualitative study. [PDF]

PLoS One
Paul S, Dayal R, Sharma AJ, Seth K, Ramesh S, Saggurti N.   +5 more
europepmc   +1 more source

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, EarlyView.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

Comparison of machine learning models to predict loss to follow-up among people with Human Immunodeficiency Virus (HIV). [PDF]

JAMIA Open
Ridgway JP, Mason JA, Friedman EE, Oliwa T, Flores J, Simon J, Ekong A, Yang TY, Schneider JA.   +8 more
europepmc   +1 more source

Sexually Transmitted Infection Prevalence and Determinants Among Sexual Health Clinic Attendees in Bucharest, Romania

International Journal of Dermatology, EarlyView.
Cross‐sectional study among 70 sexual health clinic attendees (70% MSM) in Bucharest combining multisite STI testing with knowledge, attitudes, and practices assessment. Key findings include 35.5% bacterial STI prevalence, essential extragenital testing, and cost barriers to screening uptake.
Andrei Tanasov, George‐Sorin Tiplica
wiley   +1 more source

Genitourinary Tuberculosis in a Young Male With Advanced Human Immunodeficiency Virus (HIV) Diagnosed via Urinary Lipoarabinomannan Antigen (TB-LAM): A Case Report From a High-Burden Setting. [PDF]

Cureus
Rodriguez Marino JM, Caballero Garcia M, Vargas A, Tueros B, Pelaez Callalli DS, Pelaez Callalli BS, Rodriguez F.   +6 more
europepmc   +1 more source

Neuroinflammation as a result of non‐neurotropic herpesvirus infection

Immunology &Cell Biology, EarlyView.
Atypical memory B cells (ABCs) might stimulate autoreactive T cells to cause neuroinflammation and CNS myeloid cell activation during MS. Abstract The non‐neurotropic Epstein Barr virus (EBV) has been suggested to initiate the prodromal phase of multiple sclerosis (MS), often years before the first clinical symptoms. This review discusses mechanisms by
Christian Münz
wiley   +1 more source

Frequency and Genotype Diversity of Human Pegiviruses (HPgV) in People Infected with Human Immunodeficiency Virus (HIV). [PDF]

Infect Dis Clin Microbiol
Yücebağ-Duranay E, Kocazeybek BS, Kuşkucu MA.   +2 more
europepmc   +1 more source

Pathogenicity of human immunodeficiency virus(HIV).

Uirusu, 1991
openaire   +3 more sources